Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT02876302

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Conditions: Inflammatory Breast Cancer (IBC)

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 23

Sponsor: Dana-Farber Cancer Institute

Location: Dana-Farber Cancer Institute Boston Massachusetts

Summary

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. * Paclitaxel (also called Taxol) * Doxorubicin also called Adriamycin * Cyclophosphamide, also called Cytoxan

Eligibility Criteria

Inclusion Criteria: * Participants must have histologically confirmed invasive breast cancer. All histologic subtypes are eligible. * Patients must have known ER, PR, and HER2 status defined as triple-negative breast cancer (TNBC), defined as: --ER and PR \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02876302). StuddyBuddy aggregates publicly available trial information.